We report successful outcome in 13 children (median age 2.2 years) with high-risk AML who received SCT from an unrelated (11) or identical sibling (2) donor after a preparative regimen consisting of BU, CY and melphalan. Three children were 'poor'-risk in first CR, three in the second CR, five in PR and two had resistant disease. Immunotherapeutic strategies were employed to maximize a GVL response escalating through a reduced dose of alemtuzumab, early taper of CsA, donor lymphocyte infusion and treatment with a-IFN. Ten out of 13 (77%) children are alive in CR at a median of 41 months (range: 17-88) from SCT. There was no TRM, but three children relapsed and died 3, 4 and 17 months after SCT. These encouraging early results warrant further studies in children with very high-risk AML.
Introduction
The overall survival for pediatric AML has increased dramatically over the last 30 years. Children with 'good', 'standard' and 'poor'-risk de novo AML, as defined and treated according to the Medical Research Council AML 12 protocol, achieved a 5-year survival from CR of 84, 76 and 47%, respectively, with relapse being the major cause of treatment failure. Allo-SCT was advocated for 'poor'-risk children, including children with more than 15% blasts in the BM after the first course of chemotherapy; those with adverse cytogenetic abnormalities of À5, À7, del(5q) and abn(3q); and those with complex karyotype and without favorable genetic abnormalities (t(8;21), inv (16) , t (15;17) ). 1 However, SCT using conditioning with TBI 1440 cGY and CY 120 mg/kg did not translate into an improved disease-free survival, and the use of unrelated donors in 'poor'-risk patients was associated with a significant TRM. 2 Most children with relapsed AML proceed to SCT once a second CR has been achieved; up to 40% of children are salvaged in this way. However, those that relapse within 1 year from the time of diagnosis have a poorer prognosis. 3, 4 Children who are refractory to de novo or salvage chemotherapy have a dismal prognosis with less than 20% of children being salvaged by SCT. 5 A poor prognosis has also been associated with secondary AML: 15% at 3 years. 6 Conflicting results have been reported comparing TBI and CY versus BU and CY in SCT for AML. 7 SCT data in myelodysplastic syndrome reported by Locatelli et al., 8 and subsequently in juvenile myelomonocytic leukemia, 9 showed a better event-free survival and a lower relapse incidence with BU, CY, melphalan (Mel) in comparison with TBI-conditioning regimens. In view of the young age of our patient population (median age 2.2 years), we chose to use BU-CY-Mel to reduce the risk of severe radiationinduced growth retardation 10, 11 endocrine and neurological sequelae. [12] [13] [14] Given the high risk of relapse, immunotherapeutic strategies were employed to enhance a GVL effect. 15 We report our experience over the last 8 years using BU-CY-Mel in the setting of high-risk AML.
Methods

Patients
Between December 2000 and February 2008, 13 children of a median age of 2.2 years (range: 1.4-5.7) were transplanted for high-risk AML at Great Ormond Street Hospital. Donors were unrelated (n ¼ 11) (fully matched for HLA A, B, C (antigenic) and DRB1, DQB1 (allelic) (n ¼ 6), one antigen-mismatched (n ¼ 5)) or identical siblings (n ¼ 2). Characteristics of the children are shown in Table 1 . Three were in first CR, three in second CR, five in PR (5-15% blasts) and two had resistant disease (415% blasts) before SCT. SCT in high-risk pediatric AML
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Nine children with de novo AML were initially treated according to the UK Medical Research Council AML 12 protocol. Four 'poor'-risk children went to SCT in CR1: three with complex cytogenetics and one who had 47% blasts after course 1. Five children relapsed early at 4, 9, 10, 14 and 14 months from the time of diagnosis: three of them achieved CR, whereas the other two achieved PR after salvage chemotherapy (Table 2) .
All children had AML by FAB criteria; three children had an antecedent myelodysplastic syndrome (n ¼ 2) or juvenile myelomonocytic leukemia (n ¼ 1), whereas one child had secondary AML. Table 1 . All children except for patient 6 received fresh T-replete stem cells with red cells removed according to group mismatch between donor/ recipient. In patient 6, the graft was ex vivo T-cell depleted with CAMPATH-1M and a T-cell add-back of 5 Â 10 5 /kg was given.
Preparative regimen, transplantation and supportive care
Antimicrobial prophylaxis was given as described previously. 16 Immunotherapy A number of immunotherapeutic strategies were employed with the aim of maintaining 100% donor chimerism and/or achieving limited GVHD: (1) reducing the dose of alemtuzumab by 50%; (2) early cessation of CsA beginning taper at 1-2 months post SCT (depending on donor match/ stem cell source) in case of absence of acute GVHD, and cessation 2-4 weeks later; (3) donor lymphocyte infusion (DLI) 10 
Analysis of chimerism
Chimerism analysis was performed as described previously. 16 
Results and discussion
Engraftment, chimerism and relapse
The median time to neutrophil count 40.5 Â 10 9 /l was 16 days (range: 11-26), and to an unsupported platelet count 420 Â 10 9 /l was 18 days (range: 9-29). All children had achieved 100% donor chimerism at engraftment, which has been maintained in 10/13. Three out of 13 children developed mixed chimerism post SCT: two at 2 months and one at 4 months. Patient 8 was 79% donor in whole blood, patient 11 was 52% donor in whole blood and patient 13 was 20% donor in whole blood at this time, and they went on to relapse at 3, 17, and 4 months after transplant, respectively (Table 2) .
Immunotherapy and GVHD
The standard dose of alemtuzumab was 0.2 mg/kg/day for 5 days. Four out six children undergoing MUD SCT, three of whom were not in remission (41, 26 and 10% blasts) at the time of SCT and one child with a very early relapse of AML (4 months), received a 50% reduced dose of alemtuzumab (0.2 mg/kg Â 2 days and 0.1 mg/kg Â 1 day). CsA was stopped at a median of 87 days after SCT for the whole group (interquartile range: 2.5-3.2 months). The decision to taper was based on the physician's choice, bearing in mind the degree of HLA match, stem-cell source and severity of GVHD. In five children, CsA was stopped very early (within 2 months post transplant). Four children discontinued CsA early (within 3 months after SCT). Five of 13 children developed acute GVHD, and three developed grade II and two grade I GVHD. Six children developed chronic GVHD, four with skin (that is, limited) and two with gut involvement (that is, extensive) ( Table 2) . 17 In patient 11, who developed recipient T-cell chimerism 2 months after SCT despite reduced dose of alemtuzumab and very early taper of CsA, a DLI of 10 6 /kg was administered followed by a-IFN. He developed grade I acute GVHD and limited chronic GVHD, and the donor T-cell chimerism increased to 78% (by CD3 þ mononuclear cells) but never became full donor. He relapsed 17 months after the transplant. In patient 7, who developed no GVHD after matched sibling donor BMT and cessation of CsA at day 32, a-IFN alone was administered: he developed limited chronic GVHD and remained in remission at 16.5 months. Patient 13 developed no GVHD despite cessation of CYA 2 months post SCT and administration of a-IFN 3 months post SCT; she relapsed at 4 months with no further response to fludarabine/ cytarabine (FLA) chemotherapy and DLI.
Toxicity, survival and quality of life Eleven out of 13 children had grade III mucositis. Other complications are listed in Table 2 , but there was no TRM. Ten of 13 (77%) children are alive in CR at a median of 36 months (range: 3-12) from SCT with Lansky scores of 90-100%. Three children relapsed at 3, 4 and 17 months after SCT; two died of disease progression shortly after and one had a second graft from another unrelated donor and died abroad of pneumonitis of unknown cause ( Table 2) .
Discussion
This is the first report of the use of BU-CY-Mel in children with high-risk AML, and the results are encouraging. Although too small for statistical analysis, the overall survival data compare favorably with historical data. [18] [19] [20] In our cohort, 10 out of 13 children are alive in CR with good performance status at a median follow-up of 3.4 years.
The lack of procedural-related mortality and the initial achievement of 100% donor chimerism in all 13 children provided a platform for individualized and escalating immunotherapeutic strategies, which we hypothesize, alongside the use of non-genoidentical donors, may have played a substantial role in preventing relapse by enabling a stronger GVL effect. [21] [22] [23] In 10/13 (77%) children, 100% donor chimerism was sustained with limited GVHD occurring in 7/13 (54%) children. No data on the use of a-IFN for relapse of acute leukemia are currently available, but the use of a lower dose DLI in combination with a-IFN might allow the prompt onset of limited, yet sustained, GVHD with an associated GVL effect. The lack of GVHD in four patients who are alive and well might suggest the possibility of a GVL effect with subclinical or no GVHD. However, the fact that 2/3 patients who relapsed had no overt GVHD confirms that the goal should remain to achieve clinical GVHD in these patients. This might be facilitated by reducing the Campath dose in all patients and/or earlier tapering of CYA.
Previous data have reported a better outcome following SCT for AML among children under 10 years of age. 4, 24 The median age of our series of children was just over 2 years. It could be argued that young age may have influenced the good outcome in our patient group, although very recent data from CIBMTR have suggested an increased risk of relapse in children under 5 years of age (Davies SM, personal communication).
These early promising data suggest that the combination of BU-CY-Mel should be considered for further study as conditioning regimen in children with high-risk AML who are proceeding to SCT. Given the substantial risk of relapse, and in the absence of GVHD, this approach should be used as a platform for escalating immunotherapeutic strategies with the endpoint of sustaining 100% donor chimerism or achieving limited GVHD to maximize the potential for a GVL effect. 
